Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026?
AnaptysBio, Inc. (NASDAQ:ANAB) is one of the best performing healthcare stocks so far in 2026. Piper Sandler cut the price target on AnaptysBio, Inc.
Anaptysbio Inc (ANAB)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | EcoR1 Capital Oleg Nodelman | 11,820,141 | $437,030,013 | 18.55% | |
| 2. | Tang Capital Management Kevin C. Tang | 1,996,318.5 | $73,810,549 | -1% | 3.75% |
| 3. | Palo Alto Investors William Leland Edwards | 957,241.5 | $35,392,409 | -8% | 5.41% |
| 4. | 683 Capital Partners Ari Zweiman | 937,500 | $34,662,500 | -4% | 1.81% |
| 5. | D E Shaw D. E. Shaw | 868,944 | $32,127,756 | -14% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $12.95 | 6,646 | $86,069.69 | 7,880,094 | 2025-01-02 | Filing | |
| $12.93 | 13,268 | $171,512.78 | 7,873,448 | 2024-12-31 | Filing | |
| $12.92 | 65,184 | $842,059.95 | 7,860,180 | 2024-12-30 | Filing | |
| $36.50 | 273,972 | $9,999,978.00 | 7,794,996 | 2024-08-14 | Filing | |
| $23.25 | 165,000 | $3,835,755.00 | 7,520,424 | 2021-05-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $57.40 | 522 | $29,962.23 | 31,622 | 2026-03-30 | Filing | |
| $56.70 | 7,527 | $426,782.41 | 32,144 | 2026-03-30 | Filing | |
| $55.71 | 12,596 | $701,706.79 | 39,671 | 2026-03-30 | Filing | |
| $65.99 | 100 | $6,599.00 | 495,965 | 2026-03-27 | Filing | |
| $65.20 | 3,038 | $198,072.13 | 496,065 | 2026-03-27 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,522,070 | $93,249,334 | 0% | |
| 2. | 1,490,857.5 | $55,121,984 | 0% | |
| 3. | 1,488,667.5 | $55,041,000 | 0% | |
| 4. | 1,410,000 | $52,132,400 | 2.69% | |
| 5. | 1,279,726.5 | $47,315,754 | 0% |
News See All
10 Best Performing Healthcare Stocks So Far in 2026
She was of the view that the backdrop at present is featuring geopolitical tensions, Fed policy uncertainty, inflation concerns, and still, it is incredible that the stock market is at record highs.
AnaptysBio's Rosnilimab Shows 'Best-in-Disease' Profile in Phase 2b RA Trial
On June 3, AnaptysBio Inc.
11 Unstoppable Growth Stocks to Invest in Now
BlackRock highlighted that the trade conflict between the US and China continues to cause major economic disruptions.
13 Best Short Squeeze Stocks To Buy Now
In this piece, we will take a look at the 13 best short squeeze stocks to buy now.
AnaptysBio, Inc. (ANAB): Hedge Funds Are Snapping Up
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don't make them change their opinion towards a...
AnaptysBio, Inc. (ANAB): Hedge Funds Are Snapping Up
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios.
10 Best Biotech Stocks to Buy According to Alan Frazier's Frazier Healthcare Partners
In this article, we discuss the 10 best biotech stocks to buy according to Alan Frazier.
Hedge Funds Cashed Out Of AnaptysBio, Inc. (ANAB) Too Early
The Insider Monkey team has completed processing the quarterly 13F filings for the March quarter submitted by the hedge funds and other money managers included in our extensive database.
Is ANAB Stock A Buy or Sell?
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don't make them change their opinion towards a...
Hedge Fund Resource Center